IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer

Cancer Letters

Volumn 335, Issue 1, 2013, Pages 153-159

  Bitelman, Connie ^a   Sarfstein, Rive ^a   Sarig, Menahem ^b   Attias Geva, Zohar ^a   Fishman, Ami ^b   Werner, Haim ^a   Bruchim, Ilan ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

Author keywords

Endometrial cancer; IGF1; IGF1 receptor; MK 0646; Uterine serous carcinoma

Indexed keywords

CISPLATIN; DALOTUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MOLECULAR TARGETED THERAPY; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84878447701     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.009     Document Type: Article

References (43)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA. Cancer. J. Clin. 2009, 59(2009):225-249.
2. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983, 15:10-17.
3. Lax S.F. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004, 444:213-223.
4. Goff B.A., Kato D., Schmidt R.A., Ek M., Ferry J.A., Muntz H.G., Cain J.M., Tamimi H.K., Figge D.C., Greer B.E. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol. Oncol. 1994, 54:264-268.
5. Hamilton C.A., Cheung M.K., Osann K., Chen L., Teng N.N., Longacre T.A., Powell M.A., Hendrickson M.R., Kapp D.S., Chan J.K. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br. J. Cancer. 2006, 94:642-646.
6. Boruta D.M., Gehrig P.A., Groben P.A., Bae-Jump V., Boggess J.F., Fowler W.C., Van Le L. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?. Cancer 2004, 101:2214-2221.
7. Salvesen H.B., Haldorsen I.S., Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 2012, 13:e353-361.
8. Banno K., Kisu I., Yanokura M., Tsuji K., Masuda K., Ueki A., Kobayashi Y., Yamagami W., Nomura H., Tominaga E., Susumu N., Aoki D. Biomarkers in endometrial cancer: possible clinical applications (Review). Oncol. Lett. 2012, 3:1175-1180.
9. Pallares J., Martinez-Guitarte J.L., Dolcet X., Llobet D., Rue M., Palacios J., Prat J., Matias-Guiu X. Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J. Pathol. 2004, 204:569-577.
10. LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Rev. 1995, 16:143-163.
11. Baserga R., Hongo A., Rubini M., Prisco M., Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta. 1997, 1332:F105-F126.
12. Werner H. The molecular basis of IGF-I receptor gene expression in human cancer. Insulin-like Growth Factors 2003, 346-356. Landes Bioscience, Georgetown, Texas. D. LeRoith, W. Zumkeller, R. Baxter (Eds.).
13. Werner H., Roberts C.T. The IGF-I receptor gene: a molecular target for disrupted transcription factors. Gene Chromosomes Cancer 2003, 36:113-120.
14. Werner H., Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol. Metab. 2006, 17:236-242.
15. Khandwala H.M., McCutcheon I.E., Flyvbjerg A., Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrine Rev. 2000, 21:215-244.
16. McCampbell A.S., Broaddus R.R., Loose D.S., Davies P.J. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin. Cancer Res. 2006, 12:6373-6378.
17. Pengchong H., Tao H. Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma. Eur. J. Gynaecol. Oncol. 2011, 32:660-664.
18. Werner H., Bruchim I. The insulin-like growth factor-I receptor as an oncogene. Arch. Physiol. Biochem. 2009, 115:58-71.
19. Atzori F., Tabernero J., Cervantes A., Prudkin L., Andreu J., Rodriguez-Braun E., Domingo A., Guijarro J., Gamez C., Rodon J., Di Cosimo S., Brown H., Clark J., Hardwick J.S., Beckman R.A., Hanley W.D., Hsu K., Calvo E., Rosello S., Langdon R.B., Baselga J. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 2011, 17:6304-6312.
20. Brasaemle D.L., Attie A.D. Microelisa reader quantitation of fixed, stained, solubilized cells in microtitre dishes. Biotechniques 1988, 6:418-419.
21. Attias-Geva Z., Bentov I., Ludwig D.L., Fishman A., Bruchim I., Werner H. Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells. Eur. J. Cancer. 2011, 47:1717-1726.
22. Duriez P.J., Shah G.M. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem. Cell Biol. [Biochimie et biologie cellulaire] 1997, 75:337-349.
23. Bruchim I., Attias Z., Werner H. Targeting the IGF1 axis in cancer proliferation. Expert Opin. Ther. Targets. 2009, 13:1179-1192.
24. Ayabe T., Tsutsumi O., Sakai H., Yoshikawa H., Yano T., Kurimoto F., Taketani Y. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr. J. 1997, 44:419-424.
25. Petridou E., Koukoulomatis P., Alexe D.M., Voulgaris Z., Spanos E., Trichopoulos D. Endometrial cancer and the IGF system: a case-control study in Greece. Oncology 2003, 64:341-345.
26. Gunter M.J., Hoover D.R., Yu H., Wassertheil-Smoller S., Manson J.E., Li J., Harris T.G., Rohan T.E., Xue X., Ho G.Y., Einstein M.H., Kaplan R.C., Burk R.D., Wylie-Rosett J., Pollak M.N., Anderson G., Howard B.V., Strickler H.D. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol. Biomarkers Prev. 2008, 17:921-929.
27. Hirano S., Ito N., Takahashi S., Tamaya T. Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur. J. Gynaecol. Oncol. 2004, 25:187-191.
28. Pavelic J., Radakovic B., Pavelic K. Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol. Oncol. 2007, 105:727-735.
29. Attias-Geva Z., Bentov I., Fishman A., Werner H., Bruchim I. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines. Gynecol. Oncol. 2011, 121:383-389.
30. King E.R., Wong K.K. Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat. Anticancer Drug Discov. 2012, 7:14-30.
31. Broussas M., Dupont J., Gonzalez A., Blaecke A., Fournier M., Corvaia N., Goetsch L. Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor. Int. J. Cancer 2009, 124:2281-2293.
32. Pandini G., Wurch T., Akla B., Corvaia N., Belfiore A., Goetsch L. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur. J. Cancer. 2007, 43:1318-1327.
33. Cao L., Yu Y., Darko I., Currier D., Mayeenuddin L.H., Wan X., Khanna C., Helman L.J. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008, 68:8039-8048.
34. Sehat B., Tofigh A., Lin Y., Trocme E., Liljedahl U., Lagergren J., Larsson O. SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Science Signaling 2010, 3. pp. ra10.
35. Baserga R. The decline and fall of the IGF-I receptor. J. Cell Physiol. 2013, 228:675-679.
36. Hailey J., Maxwell E., Koukouras K., Bishop W.R., Pachter J.A., Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol. Cancer. Ther. 2002, 1:1349-1353.
37. Maloney E.K., McLaughlin J.L., Dagdigian N.E., Garrett L.M., Connors K.M., Zhou X.M., Blattler W.A., Chittenden T., Singh R. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 2003, 63:5073-5083.
38. Fagan D.H., Uselman R.R., Sachdev D., Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res. 2012, 72:3372-3380.
39. Olmos D., Martins A.S., Jones R.L., Alam S., Scurr M., Judson I.R. Targeting the insulin-like growth factor 1 receptor in ewing's sarcoma: reality and expectations. Sarcoma 2011, 2011:402508.
40. Gualberto A., Hixon M.L., Karp D.D., Li D., Green S., Dolled-Filhart M., Paz-Ares L.G., Novello S., Blakely J., Langer C.J., Pollak M.N. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br. J. Cancer 2011, 104:68-74.
41. de Bono J.S., Attard G., Adjei A., Pollak M.N., Fong P.C., Haluska P., Roberts L., Melvin C., Repollet M., Chianese D., Connely M., Terstappen L.W., Gualberto A. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin. Cancer Res. 2007, 13:3611-3616.
42. Asmane I., Watkin E., Alberti L., Duc A., Marec-Berard P., Ray-Coquard I., Cassier P., Decouvelaere A.V., Ranchere D., Kurtz J.E., Bergerat J.P., Blay J.Y. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur. J. Cancer 2012.
43. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin. Cancer Res. 2012, 18:40-50.